Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Oct;64(4):780–784. doi: 10.1038/bjc.1991.398

Immunohistochemical and other features of breast carcinomas presenting clinically compared with those detected by cancer screening.

W K Cowan 1, B Angus 1, J Henry 1, I P Corbett 1, W A Reid 1, C H Horne 1
PMCID: PMC1977686  PMID: 1680369

Abstract

Features of 111 mammary carcinomas derived from breast cancer screening were compared with those of 69 carcinomas presenting 'clinically'. Screen detected cancers were smaller, had less likelihood of nodal metastases, included a higher proportion of in situ tumours and if invasive, tended to be of lower grade. Using immunohistochemical methods, the expression of c-erbB-2 oncoprotein, epidermal growth factor receptor (EGFR) and cathepsin D were compared in the two groups. A similar proportion of screened and unscreened tumours expressed c-erbB-2 oncoprotein and EGFR but expression of the oestrogen regulated protein cathepsin D was significantly more frequent in the screened group (P less than 0.05). Although a relatively small series, the results suggest a biological difference between 'screened' and 'clinical' tumours.

Full text

PDF
780

Images in this article

781Figure 1
on p.781

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson T. J., Lamb J., Alexander F., Lutz W., Chetty U., Forrest A. P., Kirkpatrick A., Muir B., Roberts M. M., Huggins A. Comparative pathology of prevalent and incident cancers detected by breast screening. Edinburgh Breast Screening Project. Lancet. 1986 Mar 8;1(8480):519–523. doi: 10.1016/s0140-6736(86)90882-2. [DOI] [PubMed] [Google Scholar]
  2. Barnes D. M. Breast cancer and a proto-oncogene. BMJ. 1989 Oct 28;299(6707):1061–1062. doi: 10.1136/bmj.299.6707.1061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Capony F., Rougeot C., Montcourrier P., Cavailles V., Salazar G., Rochefort H. Increased secretion, altered processing, and glycosylation of pro-cathepsin D in human mammary cancer cells. Cancer Res. 1989 Jul 15;49(14):3904–3909. [PubMed] [Google Scholar]
  4. Clark G. M., Osborne C. K., McGuire W. L. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol. 1984 Oct;2(10):1102–1109. doi: 10.1200/JCO.1984.2.10.1102. [DOI] [PubMed] [Google Scholar]
  5. Gibbs N. M. Comparative study of the histopathology of breast cancer in a screened and unscreened population investigated by mammography. Histopathology. 1985 Dec;9(12):1307–1318. doi: 10.1111/j.1365-2559.1985.tb02812.x. [DOI] [PubMed] [Google Scholar]
  6. Henry J. A., McCarthy A. L., Angus B., Westley B. R., May F. E., Nicholson S., Cairns J., Harris A. L., Horne C. H. Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. An immunohistochemical study. Cancer. 1990 Jan 15;65(2):265–271. doi: 10.1002/1097-0142(19900115)65:2<265::aid-cncr2820650214>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  7. Horne G. M., Angus B., Wright C., Needham G., Nicholson S., Harris A. L., Innes B., Horne C. H. Relationships between oestrogen receptor,epidermal growth factor receptor, ER-D5, and P24 oestrogen regulated protein in human breast cancer. J Pathol. 1988 Jun;155(2):143–150. doi: 10.1002/path.1711550211. [DOI] [PubMed] [Google Scholar]
  8. Lewis S., Locker A., Todd J. H., Bell J. A., Nicholson R., Elston C. W., Blamey R. W., Ellis I. O. Expression of epidermal growth factor receptor in breast carcinoma. J Clin Pathol. 1990 May;43(5):385–389. doi: 10.1136/jcp.43.5.385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Maudelonde T., Khalaf S., Garcia M., Freiss G., Duporte J., Benatia M., Rogier H., Paolucci F., Simony J., Pujol H. Immunoenzymatic assay of Mr 52,000 cathepsin D in 182 breast cancer cytosols: low correlation with other prognostic parameters. Cancer Res. 1988 Jan 15;48(2):462–466. [PubMed] [Google Scholar]
  10. Press M. F. Oncogene amplification and expression. Importance of methodologic considerations. Am J Clin Pathol. 1990 Aug;94(2):240–241. doi: 10.1093/ajcp/94.2.240. [DOI] [PubMed] [Google Scholar]
  11. Reid W. A., Valler M. J., Kay J. Immunolocalization of cathepsin D in normal and neoplastic human tissues. J Clin Pathol. 1986 Dec;39(12):1323–1330. doi: 10.1136/jcp.39.12.1323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Roberts M. M., Alexander F. E., Anderson T. J., Chetty U., Donnan P. T., Forrest P., Hepburn W., Huggins A., Kirkpatrick A. E., Lamb J. Edinburgh trial of screening for breast cancer: mortality at seven years. Lancet. 1990 Feb 3;335(8684):241–246. doi: 10.1016/0140-6736(90)90066-e. [DOI] [PubMed] [Google Scholar]
  13. Sainsbury J. R., Farndon J. R., Needham G. K., Malcolm A. J., Harris A. L. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet. 1987 Jun 20;1(8547):1398–1402. doi: 10.1016/s0140-6736(87)90593-9. [DOI] [PubMed] [Google Scholar]
  14. Sainsbury J. R., Malcolm A. J., Appleton D. R., Farndon J. R., Harris A. L. Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. J Clin Pathol. 1985 Nov;38(11):1225–1228. doi: 10.1136/jcp.38.11.1225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Sainsbury J. R., Nicholson S., Angus B., Farndon J. R., Malcolm A. J., Harris A. L. Epidermal growth factor receptor status of histological sub-types of breast cancer. Br J Cancer. 1988 Oct;58(4):458–460. doi: 10.1038/bjc.1988.240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Slamon D. J., Clark G. M., Wong S. G., Levin W. J., Ullrich A., McGuire W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987 Jan 9;235(4785):177–182. doi: 10.1126/science.3798106. [DOI] [PubMed] [Google Scholar]
  17. Spyratos F., Maudelonde T., Brouillet J. P., Brunet M., Defrenne A., Andrieu C., Hacene K., Desplaces A., Rouëssé J., Rochefort H. Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet. 1989 Nov 11;2(8672):1115–1118. doi: 10.1016/s0140-6736(89)91487-6. [DOI] [PubMed] [Google Scholar]
  18. Stebbings W. S., Anderson E., Puddefoot J. R., Vinson G. P., Gilmore O. J., Plowman P. N. Variations in steroid receptor status with disease stage in breast cancer. Eur J Surg Oncol. 1989 Aug;15(4):322–327. [PubMed] [Google Scholar]
  19. Tandon A. K., Clark G. M., Chamness G. C., Chirgwin J. M., McGuire W. L. Cathepsin D and prognosis in breast cancer. N Engl J Med. 1990 Feb 1;322(5):297–302. doi: 10.1056/NEJM199002013220504. [DOI] [PubMed] [Google Scholar]
  20. Thorpe S. M., Rochefort H., Garcia M., Freiss G., Christensen I. J., Khalaf S., Paolucci F., Pau B., Rasmussen B. B., Rose C. Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res. 1989 Nov 1;49(21):6008–6014. [PubMed] [Google Scholar]
  21. Tinnemans J. G., Beex L. V., Wobbes T., Sluis R. F., Raemaekers J. M., Benraad T. Steroid-hormone receptors in nonpalpable and more advanced stages of breast cancer. A contribution to the biology and natural history of carcinoma of the female breast. Cancer. 1990 Sep 15;66(6):1165–1167. doi: 10.1002/1097-0142(19900915)66:6<1165::aid-cncr2820660615>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  22. Toi M., Nakamura T., Mukaida H., Wada T., Osaki A., Yamada H., Toge T., Niimoto M., Hattori T. Relationship between epidermal growth factor receptor status and various prognostic factors in human breast cancer. Cancer. 1990 May 1;65(9):1980–1984. doi: 10.1002/1097-0142(19900501)65:9<1980::aid-cncr2820650917>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  23. Varley J. M., Swallow J. E., Brammar W. J., Whittaker J. L., Walker R. A. Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene. 1987;1(4):423–430. [PubMed] [Google Scholar]
  24. Waterfield M. D., Mayes E. L., Stroobant P., Bennet P. L., Young S., Goodfellow P. N., Banting G. S., Ozanne B. A monoclonal antibody to the human epidermal growth factor receptor. J Cell Biochem. 1982;20(2):149–161. doi: 10.1002/jcb.240200207. [DOI] [PubMed] [Google Scholar]
  25. Westley B., Rochefort H. Estradiol induced proteins in the MCF7 human breast cancer cell line. Biochem Biophys Res Commun. 1979 Sep 27;90(2):410–416. doi: 10.1016/0006-291x(79)91250-6. [DOI] [PubMed] [Google Scholar]
  26. Wright C., Angus B., Nicholson S., Sainsbury J. R., Cairns J., Gullick W. J., Kelly P., Harris A. L., Horne C. H. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 1989 Apr 15;49(8):2087–2090. [PubMed] [Google Scholar]
  27. Zhou D., Battifora H., Yokota J., Yamamoto T., Cline M. J. Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer. Cancer Res. 1987 Nov 15;47(22):6123–6125. [PubMed] [Google Scholar]
  28. van de Vijver M. J., Peterse J. L., Mooi W. J., Wisman P., Lomans J., Dalesio O., Nusse R. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med. 1988 Nov 10;319(19):1239–1245. doi: 10.1056/NEJM198811103191902. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES